Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Study of VX-661 plus ivacaftor in people with CF who have two copies of the F508del CFTR mutation. , protocol number NCT02508207 VERTEX VX-661-111

    This study evaluated the safety and effectiveness of the CFTR modulator drug VX-661 in combination with ivacaftor (Symdeko®). This study was for people with CF who have two copies of the F508del CFTR mutation.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      6

    • Length of Participation:

      60 days

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    An Ocular Safety Study of Kalydeco-Treated Children 11 Years of Age or Younger with CF , protocol number Vertex VX-770-115

    This trial is designed to evaluate the risk of of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of children with Cystic Fibrosis who are 11 years of age or younger at the time of ivacaftor (Kalydeco) treatment initiation and are receiving or planning to receive commercially-available ivacaftor (Kalydeco) in the US.

    • Age:

      6 Years to 11 Years

    • Mutation(s):

      One Copy F508del or No Copies F50del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      2 years

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 3 study of lumacaftor and ivacaftor in which cystic fibrosis with advanced lung disease. , protocol number Vertex VX-809-106

    This study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drugs lumacaftor and ivacaftor in people with advanced lung disease.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      Less than 40%

    • Number of Visits:

      14

    • Length of Participation:

      52 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of lumarcaftor and ivacaftor in children with cystic fibrosis , protocol number Vertex VX-809-109

    This study is taking place at multiple care centers across the U.S. It will evaulate the safety and effectiveness of the drugs lumacaftor and ivacaftor in children with cystic fibrosis.

    • Age:

      6 Years to 11 Years

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      70% to 105%

    • Number of Visits:

      5

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • BehavioralCompleted with results Location: Multiple care centres across the US

    Study of adherence to lumacaftor/ivacaftor using a smart pill bottle device. , protocol number NCT02823470 VERTEX VX-809-114

    This study evaluated the impact of a smart pill bottle device on adherence to lumacaftor/ivacaftor (Orkambi®). This study was for people with CF who were not currently being treated with lumacaftor/ivacaftor (Orkambi®) prior to enrolling in the study.

    • Age:

      16 Years and Older

    • Mutation(s):

      Two Copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      7

    • Length of Participation:

      48 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites

    Phase 2 study of CTP-656 in aduts with CF who are currently taking ivacaftor (Kalydeco) , protocol number NCT02971839 CP656.2001

    This study will evaluate the safety and effectiveness of the drug, CTP-656 in adults with Cystic Fibrosis who have a gating mutation and are currently taking ivacaftor (KALYDECO)

    • Age:

      18 years and older

    • Mutation(s):

      One copy F508del or no copies F508del

    • FEV1% Predicted:

      60-90%

    • Number of Visits:

      6

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    RESTORE-CF: Phase 1/2 study of MRT5005 in adults with cystic fibrosis (Parts A & B) , protocol number NCT03375047 -Translate Bio RESTORE-CF MRT5005-101

    This first human study is taking place at multiple care centers across the US. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      50-90%

    • Number of Visits:

      21

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Study of effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in people with CF who have one copy of the F508del CFTR mutation (Vertex VX17-445-102) , protocol number NCT03525444 VX17-445-102

    This study evaluated the effectiveness and safety the CFTR modulator drug VX-445 (elexacaftor) in combination with texacaftor and ivacaftor (ELX/TEZ/IVA). This triple combination drug is known as Trikafta. This study was for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.

    • Age:

      12 years and older

    • Mutation(s):

      One copy F508del

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      10

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Study of VX-445 plus ivacaftor and tezacaftor in people with CF who have two copies of the F508 del CFTR mutation (Vertex VX17-445-103) , protocol number NCT03525548 VX17-445-103

    This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with ivacaftor and tezacaftor. This triple combination is known as Trikafta. This study was for people with CF ages 12 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor plus ivacaftor.

    • Age:

      12 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      7

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Displaying results 171-179 (of 179)
     |<  <  9 - 10 - 11 - 12 - 13 - 14 - 15 - 16 - 17 - 18 >  >|